Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by brad129on Dec 10, 2020 9:56am
144 Views
Post# 32075956

RE:RE:RE:Why an analyst forecast of $5.13 CAD?

RE:RE:RE:Why an analyst forecast of $5.13 CAD?

I remember the price being all over the map just look back at the posts in August you will see.

a quick google search gives you the info this was the top quote that came up for me.
 

For the current 2020 financial year, Clarus expects revenues of around 7.2 million US dollars in 2020 (almost exclusively from Covid-19 tests). ... With Covid testing volume and revenue expected to accelerate, Clarus expects Q3 revenue of $ 2.7 million and an additional $ 4 million in Q4.Aug 29, 2020
As you can see we didn't hit his Q3 numbers, missed by 30+ percent. Maybe he is just moving the prediction further into the future.



davewho wrote: not sure if thats the case. It was always in C$ according to my TD account. It shows the new target of $5.13C and a reiterated buy by the Analyst Atkinson from Clarus dated 08Dec. After the latest CC. It does convert to slightly over the $4 mark needed for Nas listing.

 

<< Previous
Bullboard Posts
Next >>